AR067646A1 - Ariloxazoles sustituidos y su uso - Google Patents
Ariloxazoles sustituidos y su usoInfo
- Publication number
- AR067646A1 AR067646A1 ARP080103173A ARP080103173A AR067646A1 AR 067646 A1 AR067646 A1 AR 067646A1 AR P080103173 A ARP080103173 A AR P080103173A AR P080103173 A ARP080103173 A AR P080103173A AR 067646 A1 AR067646 A1 AR 067646A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- hydroxy
- substituted
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Abstract
Se refiere a procedimientos para su preparacion, a su uso para el tratamiento y/o la profilaxis de enfermedades, así como a su uso para la preparacion de medicamentos para el tratamiento y/o la profilaxis de enfermedades, preferiblemente para el tratamiento y/o la prevencion de enfermedades cardiovasculares y metabolicas. Reivindicacion 1: Compuesto de formula (1) en la que A representa O o S, R1 representa hidrogeno o alquilo C1-4, R2 representa hidrogeno o alquilo C1-4 que puede estar sustituido con hidroxi, alcoxi C1-4 o hasta tres veces con fluor o R1 y R2 están unidos entre sí y forman, junto con el átomo de carbono al que están unidos, un anillo de ciclopropano o ciclobutano, R3 representa hidrogeno, halogeno o alquilo C1-4, R4 y R5 son iguales o distintos y representan independientemente entre si hidrogeno o alquilo C1-6 que puede estar sustituido una o dos veces, de forma igual o distinta, con hidroxi, alcoxi C1-4, amino, monoalquil C1-4-amino, dialquil C1-4-amino, carboxilo, alcoxi C1-4-carbonilo y/o un heterociclo de 4 a 7 miembros, en los que el heterociclo citado contiene uno o dos heteroátomos de anillo del grupo de N, O y/o S y puede estar sustituido a su vez una o dos veces, de forma igual o distinta, con alquilo C1-4, hidroxi, oxo y/o alcoxi C1-4,o R4 y R5 forman, junto con el átomo de nitrogeno al que están unidos, un heterociclo de 4 a 7 miembros, que contiene otro heteroátomo de anillo del grupo de N, O o S y puede estar sustituido una o dos veces, de forma igual o distinta, con alquilo C1-4, hidroxi, oxo y/o alcoxi C1-4, y o bien (1) (i) R6 representa arilo C6-10 o heteroarilo de 5 a 10 miembros con hasta tres heteroátomos de anillo del grupo de N, O y/o S, que pueden estar sustituidos respectivamente una a tres veces, de forma igual o distinta, con halogeno, nitro, ciano, alquilo C1-4, trifluorometilo, hidroxi, alcoxi C1-4, difluorometoxi, trifluorometoxi, monoalquil C1-4-aminocarbonilo, alcoxi C1-4-carbonilo y/o carboxilo, y R7 representa hidrogeno, fluor, cloro, alquilo C1-4, trifluorometilo, alcoxi C1-4-carbonilo, carboxilo o fenilo, en los que pueden estar sustituidos alquilo C1-4 con hidroxi o alcoxi C1-4 y fenilo con halogeno, ciano, alquilo C1-4 o trifluorometilo, o bien (ii) R6 representa hidrogeno o alquilo C1-4 y R7 representa fenilo o heteroarilo de 5 o 6 miembros con hasta dos heteroátomos de anillo del grupo de N, O y/o S, que pueden estar sustituidos respectivamente una o dos veces, de forma igual o distinta, con halogeno, ciano, alquilo C1-4 y/o trifluorometilo, así como sus sales, solvatos y solvatos de las sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007035367A DE102007035367A1 (de) | 2007-07-27 | 2007-07-27 | Substituierte Aryloxazole und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067646A1 true AR067646A1 (es) | 2009-10-21 |
Family
ID=39855432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103173A AR067646A1 (es) | 2007-07-27 | 2008-07-22 | Ariloxazoles sustituidos y su uso |
Country Status (15)
Country | Link |
---|---|
US (2) | US8440700B2 (es) |
EP (1) | EP2185550B1 (es) |
JP (1) | JP5307136B2 (es) |
KR (1) | KR20100039358A (es) |
CN (1) | CN101939317A (es) |
AR (1) | AR067646A1 (es) |
AT (1) | ATE531712T1 (es) |
CA (1) | CA2694270A1 (es) |
CL (1) | CL2008002076A1 (es) |
DE (1) | DE102007035367A1 (es) |
ES (1) | ES2375506T3 (es) |
PE (1) | PE20090904A1 (es) |
TW (1) | TW200922575A (es) |
UY (1) | UY31228A1 (es) |
WO (1) | WO2009015776A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
ES2428818T3 (es) * | 2008-05-29 | 2013-11-11 | Bayer Intellectual Property Gmbh | Dicianopiridinas sustituidas con 2-alcoxi y su uso |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102008062566A1 (de) * | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
WO2012051502A1 (en) * | 2010-10-14 | 2012-04-19 | University Of Utah Research Foundation | Methods and compositions related to neuroactive thiazoline compounds |
CN103570705B (zh) * | 2012-07-18 | 2017-01-25 | 中国医学科学院医药生物技术研究所 | 取代的n‑((1',3'‑杂唑‑4'‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途 |
WO2017137528A1 (en) | 2016-02-12 | 2017-08-17 | Charité - Universitätsmedizin Berlin | Adenosine a1 receptor agonist for use in treatment of status epilepticus |
WO2018153900A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern |
WO2018153897A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern |
WO2018153898A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
WO2018153895A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
WO2023158725A1 (en) * | 2022-02-17 | 2023-08-24 | Lucy Therapeutics, Inc. | Adenosine ligands for the treatment of neurological disorders |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052510A (en) | 1974-12-18 | 1977-10-04 | Sandoz, Inc. | 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity |
TW299333B (es) | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
DK0765327T3 (da) | 1994-06-16 | 1999-11-29 | Pfizer | Pyrazolo- og pyrrolopyridiner |
DE4430638A1 (de) | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel |
JPH09132529A (ja) | 1995-11-09 | 1997-05-20 | Ono Pharmaceut Co Ltd | 一酸化窒素合成酵素阻害剤 |
PL327938A1 (en) | 1996-01-17 | 1999-01-04 | Novo Nordisk As | Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application |
JP4431638B2 (ja) | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
JPH10324687A (ja) | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
US6191280B1 (en) | 1997-05-30 | 2001-02-20 | Basf Aktiengesellschaft | Method for producing substituted thiopyridines |
HUP0003999A3 (en) | 1997-07-16 | 2003-03-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19947154A1 (de) * | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
EP1261327B1 (en) | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
MXPA03000436A (es) | 2000-07-18 | 2003-06-24 | Yamanouchi Pharma Co Ltd | Medicamentos que compreden derivados de dicianopiridina. |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
JP2004515543A (ja) | 2000-12-11 | 2004-05-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類 |
ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
JP2003183254A (ja) | 2001-12-20 | 2003-07-03 | Yamanouchi Pharmaceut Co Ltd | 2−アシルアミノ−3,5−ジシアノピリジン誘導体又はその塩 |
EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
EP1388342A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
JP2006501217A (ja) | 2002-08-12 | 2006-01-12 | スージェン・インコーポレーテッド | 新規キナーゼ阻害剤としての3−ピロリル−ピリドピラゾールおよび3−ピロリル−インダゾール |
WO2004054505A2 (en) | 2002-12-12 | 2004-07-01 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
WO2005030129A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
AU2004289304A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Pyridine compounds |
US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
JP2008503443A (ja) | 2004-06-25 | 2008-02-07 | 大正製薬株式会社 | テトラヒドロピリジンで置換されたピロロピリミジン及びピロロピリジンの誘導体 |
DE102004032651A1 (de) | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
EP2316457A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
JP2008534453A (ja) | 2005-03-24 | 2008-08-28 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 再灌流傷害および再灌流障害の処置のための置換2−チオ−3,5−ジシアノ−4−フェニル−6−アミノピリジンの使用 |
US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
JP5201817B2 (ja) * | 2005-10-28 | 2013-06-05 | 大塚製薬株式会社 | 医薬組成物 |
WO2007073855A1 (en) | 2005-12-23 | 2007-07-05 | Bayer Healthcare Ag | Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases |
DE102006009813A1 (de) | 2006-03-01 | 2007-09-06 | Bayer Healthcare Ag | Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel |
AU2007246172A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
ES2428818T3 (es) | 2008-05-29 | 2013-11-11 | Bayer Intellectual Property Gmbh | Dicianopiridinas sustituidas con 2-alcoxi y su uso |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
-
2007
- 2007-07-27 DE DE102007035367A patent/DE102007035367A1/de not_active Withdrawn
-
2008
- 2008-07-15 CL CL2008002076A patent/CL2008002076A1/es unknown
- 2008-07-16 PE PE2008001198A patent/PE20090904A1/es not_active Application Discontinuation
- 2008-07-16 UY UY31228A patent/UY31228A1/es not_active Application Discontinuation
- 2008-07-17 KR KR1020107001748A patent/KR20100039358A/ko not_active Application Discontinuation
- 2008-07-17 EP EP08774012A patent/EP2185550B1/de not_active Not-in-force
- 2008-07-17 ES ES08774012T patent/ES2375506T3/es active Active
- 2008-07-17 JP JP2010518527A patent/JP5307136B2/ja not_active Expired - Fee Related
- 2008-07-17 WO PCT/EP2008/005833 patent/WO2009015776A1/de active Application Filing
- 2008-07-17 AT AT08774012T patent/ATE531712T1/de active
- 2008-07-17 US US12/671,019 patent/US8440700B2/en not_active Expired - Fee Related
- 2008-07-17 CA CA2694270A patent/CA2694270A1/en not_active Abandoned
- 2008-07-17 CN CN2008801002064A patent/CN101939317A/zh active Pending
- 2008-07-22 AR ARP080103173A patent/AR067646A1/es unknown
- 2008-07-25 TW TW097128216A patent/TW200922575A/zh unknown
-
2013
- 2013-05-14 US US13/893,344 patent/US9095582B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8440700B2 (en) | 2013-05-14 |
US9095582B2 (en) | 2015-08-04 |
EP2185550B1 (de) | 2011-11-02 |
CL2008002076A1 (es) | 2009-01-30 |
PE20090904A1 (es) | 2009-08-08 |
ES2375506T3 (es) | 2012-03-01 |
US20140162981A1 (en) | 2014-06-12 |
JP5307136B2 (ja) | 2013-10-02 |
DE102007035367A1 (de) | 2009-01-29 |
CA2694270A1 (en) | 2009-02-05 |
US20110130377A1 (en) | 2011-06-02 |
WO2009015776A1 (de) | 2009-02-05 |
CN101939317A (zh) | 2011-01-05 |
KR20100039358A (ko) | 2010-04-15 |
EP2185550A1 (de) | 2010-05-19 |
ATE531712T1 (de) | 2011-11-15 |
JP2010534693A (ja) | 2010-11-11 |
TW200922575A (en) | 2009-06-01 |
UY31228A1 (es) | 2009-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
AR062630A1 (es) | Derivados de bipiridina sustituidos y su uso | |
CY1121946T1 (el) | Νεα παραγωγα πυραζολο-πυριμιδινης και η χρηση τους ως αναστολεις malt1 | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
ES2722048T3 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
AR055744A1 (es) | Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos | |
AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
AR091838A1 (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos y su uso | |
AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
AR087273A1 (es) | 3-(fluorovinil)pirazoles y su uso | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
PE20110196A1 (es) | 5-alquinil-pirimidinas | |
AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |